| Status | In progress |
| Process | STA 2018 |
| ID number | 3828 |
Provisional Schedule
| Committee meeting: 2 | 07 December 2021 |
| Expected publication | 22 December 2021 |
Project Team
| Project lead | Shonagh D'Sylva |
Email enquiries
- If you have any queries please email TAteam2@nice.org.uk
Consultees
| Companies sponsors | Seagen Inc (tucatinib) |
| Others | Department of Health and Social Care |
| NHS England | |
| Welsh Government | |
| Patient carer groups | Breast Cancer Care & Breast Cancer Now |
| Professional groups | Association of Cancer Physicians |
| Cancer Research UK | |
| Royal College of Physicians | |
| Royal College of Radiologists |
Commentators
| Comparator companies | Amgen (trastuzumab) |
| Pfizer (trastuzumab) | |
| Pierre Fabre (vinorelbine) | |
| Roche (capecitabine, trastuzumab) | |
| General commentators | All Wales Therapeutics and Toxicology Centre |
| British National Formulary | |
| Department of Health, Social Services and Public Safety for Northern Ireland | |
| Healthcare Improvement Scotland | |
| Medicines and Healthcare products Regulatory Agency | |
| Scottish Medicines Consortium | |
| Welsh Health Specialised Services Committee | |
| Relevant research groups | Institute of Cancer Research |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 26 October 2021 - 16 November 2021 | Appraisal consultation |
| 05 October 2021 | Committee meeting: 1 |
| 12 February 2021 | Invitation to participate |
| 09 November 2020 - 07 December 2020 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 05 August 2020 | In progress. DHSC referral received |
For further information on how we develop guidance, please see our page about NICE technology appraisal guidance